Alcon (ALC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Alcon has acquired a majority interest in Aurion Biotech, according to a press release. Aurion will operate as a separate ...

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

Needham raised the firm’s price target on Alcon (ALC) to $110 from $107 and keeps a Buy rating on the shares. Following the company’s Capital ...

Deerfield Management accused Alcon of obstructing Aurion’s IPO plans so it could acquire the startup “at a discount.” ...

Mizuho raised the firm’s price target on Alcon (ALC) to $120 from $115 and keeps an Outperform rating on the shares following the capital ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

The companies will come together to advance robotic laser technology in cataract surgery; improving precision, reducing patient comfort, and providing faster recovery time. Read on to find out ...

Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser ...

Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million. The eye-care company said Monday that it would pay $14 for each Lensar share in cash ...